Pyxis Oncology, Inc. (NASDAQ:PYXS) Given Average Recommendation of “Moderate Buy” by Brokerages

Pyxis Oncology, Inc. (NASDAQ:PYXS) has received an average recommendation of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $7.20.

Several research analysts recently issued reports on PYXS shares. Guggenheim increased their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Zacks Research downgraded Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a research note on Thursday. Stephens increased their price objective on Pyxis Oncology from $5.00 to $8.00 and gave the stock an “overweight” rating in a research report on Monday, November 24th. Finally, HC Wainwright raised their target price on Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a report on Friday, December 19th.

Institutional Trading of Pyxis Oncology

A number of institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its holdings in Pyxis Oncology by 0.7% in the third quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock valued at $4,804,000 after buying an additional 14,566 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Pyxis Oncology by 2,690.9% in the 3rd quarter. Bank of America Corp DE now owns 615,922 shares of the company’s stock worth $1,367,000 after acquiring an additional 593,853 shares during the period. Longaeva Partners L.P. purchased a new position in Pyxis Oncology in the 3rd quarter valued at approximately $1,117,000. Citadel Advisors LLC acquired a new position in Pyxis Oncology during the third quarter worth $749,000. Finally, Jane Street Group LLC purchased a new stake in Pyxis Oncology during the second quarter worth $370,000. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Pyxis Oncology Price Performance

Shares of NASDAQ PYXS opened at $1.61 on Tuesday. The stock has a fifty day moving average price of $2.81 and a 200 day moving average price of $2.44. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The company has a market cap of $100.24 million, a PE ratio of -1.01 and a beta of 1.44.

Pyxis Oncology (NASDAQ:PYXS) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01. Analysts anticipate that Pyxis Oncology will post -1.04 earnings per share for the current fiscal year.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.